Nexalin Technology (NXL) EBIT Margin (2021 - 2026)
Nexalin Technology (NXL) posted EBIT Margin of 18479.69% for Q2 2026, down 30.32% on a QoQ basis from 14179.95% in Q1 2026, and down 1618347.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Nexalin Technology (NXL) EBIT Margin (2021 - 2026) Analysis & Trends
Nexalin Technology has reported EBIT Margin for 6 years, with the latest figure at 18479.69% in Q2 2026.
- On a quarterly basis, EBIT Margin fell 1618347.0% year-over-year to 18479.69% in Q2 2026; TTM through Jun 2026 was 4202.54%, a 95497.0% increase from a year earlier, with the FY2025 full-year figure at 2781.69%, up 181445.0% from the prior year.
- EBIT Margin was 18479.69% for Q2 2026 at Nexalin Technology, down from 14179.95% in the prior quarter.
- The five-year high for EBIT Margin was 53.77% in Q3 2022, with the low at 18479.69% in Q2 2026.
- Average EBIT Margin over 5 years is 5723.45%, with a median of 3691.45% recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin surged 917562 bps in 2025, then plunged 1618347 bps in 2026.
- Over 5 years, EBIT Margin stood at 1872.83% in 2022, then tumbled by 322 bps to 7910.37% in 2023, then sank by 34 bps to 10579.48% in 2024, then surged by 87 bps to 1403.86% in 2025, then slumped by 1216 bps to 18479.69% in 2026.
- The last three EBIT Margin figures came in at 18479.69% (Q2 2026), 14179.95% (Q1 2026), and 1403.86% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 19.15% |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | -18,479.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18,479.69% |
| Mar 31, 2026 | -14,179.95% |
| Dec 31, 2025 | -1,403.86% |
| Sep 30, 2025 | -12,924.30% |
| Jun 30, 2025 | -2,296.22% |
| Mar 31, 2025 | -4,903.63% |
| Dec 31, 2024 | -10,579.48% |
| Sep 30, 2024 | -6,962.11% |
| Jun 30, 2024 | -4,832.42% |
| Mar 31, 2024 | -1,364.81% |
| Dec 31, 2023 | -7,910.37% |
| Sep 30, 2023 | -10,017.57% |
| Jun 30, 2023 | -2,467.25% |
| Mar 31, 2023 | -2,550.48% |
| Dec 31, 2022 | -1,872.83% |
| Sep 30, 2022 | -53.77% |
| Jun 30, 2022 | -107.44% |
| Mar 31, 2022 | -116.02% |
| Dec 31, 2021 | -2,406.30% |
| Sep 30, 2021 | -3,207.88% |